skip to main content

COMPREHENSIVE NUTRITIONAL THERAPY ON A 60-YEAR-OLD MALNOURISHED MALE PATIENT WITH PULMONARY ADENOCARCINOMA AND ESOPHAGEAL STENOSIS

1Post Graduate Student, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia

2Clinical Nutrition Department of Bali Mandara Public Hospital, Denpasar, Bali, Indonesia

Received: 1 Jan 2025; Revised: 16 Feb 2025; Accepted: 17 Feb 2025; Available online: 30 Jul 2025; Published: 30 Jul 2025.

Citation Format:
Abstract

Background: Pulmonary adenocarcinoma with esophageal stenosis can trigger severe malnutrition due to catabolism, inflammation, and anabolic resistance compounded by impaired oral intake.

Objective: To Describe the nutritional challenges and impact enteral nutrition strategy used, evaluate its impact on body weight, nutritional status and functional capacity. Evidence based nutritional support
Method: The Subject was selected based on unique clinical feature. Malnourished patient’s journey with pulmonary adenocarcinoma and esophageal stenosis enteral nutrition via a gastrostomy tube.
60-year-old male with Shortness of breath, cough and throat obstruction causing vomiting and difficulty swallowing. Biomarker complete blood count, electrolyte test, body weight changes, BMI, Barthel index scale. Weight loss exceeding 10kg within three months, required assistance for daily activities. Examination severe loss of subcutaneous fat and muscle mass, Bedridden status. Body weight of 54kg, height 172cm, BMI of 18,25kg/m². Laboratory indicated anemia and hyponatremia RBC (3.70 x 10^6/µL), HGB (7.8 g/dL), HCT (26.2%), MCV (70.8fL), MCH (21.1pg), MCHC (29.8g/dL), and Na (121mmol/L). Diagnosed in January 2024 with pulmonary adenocarcinoma with esophageal stenosis, necessitating gastrotomy tube. Nutritional intervention adjustments from oral to enteral feeding formulas and caloric targets. Gradual increase nutritional therapy, initial target of 40kcal/kg and 1.3g protein/kg, providing 2160kcal and 85g protein daily. The diet began at 15 kcal/kg, with supplementation. Follow-ups reaching 2560kcal and 100g protein. Assessment since July 6 until October 14. Location at Bali Mandara Hospital.

Results: Weight gain 54 kg to 61 kg. an increase in caloric intake to 2500 kcal/day, tolerated enteral feeding well, without complication. Improved energy, improve functional capacity, better lab values, preparing him for radiotherapy. Caloric escalation countering anabolic resistance. Protein intake stimulates muscle synthesis. Omega-3fattyacids reduce inflammation, Zinc support immunity, Vitamin B6 support hematopoiesis, VCO quick energy for hypermetabolism.

Conclusion: Comprehensive nutritional therapy with supplementation improved nutritional status and stabilized metabolic state in this patient.

Note: This article has supplementary file(s).

Fulltext View|Download |  common.other
Informed Consent
Subject
Type Other
  Download (277KB)    Indexing metadata
 Research Instrument
ethical clearance
Subject
Type Research Instrument
  Download (391KB)    Indexing metadata
Keywords: malnutrition; pulmonary adenocarcinoma; esophageal stenosis; nutritional therapy

Article Metrics:

  1. Edwards JG, Chansky K, Van Schil P, Nicholson AG, Boubia S, Brambilla E, Donington J, Galateau-Sallé F, Hoffmann H, Infante M, Marino M, Marom EM, Nakajima J, Ostrowski M, Travis WD, Tsao MS, Yatabe Y, Giroux DJ, Shemanski L, Crowley J, Krasnik M, Asamura H, Rami-Porta R; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol. 2020;15(3):344-359. doi: 10.1016/j.jtho.2019.10.019
  2. Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):110-118. doi: 10.3978/j.issn.2218-6751.2015.01.01
  3. Zhang B, Wu J, Guo P, Wang Y, Fang Z, Tian J, Yu Y, Teng W, Luo Y, Li Y. Down-regulation of SREBP via PI3K/AKT/mTOR pathway inhibits the proliferation and invasion of non-small-cell lung cancer cells. Onco Targets Ther. 2020;13:8025-8036. doi: 10.2147/OTT.S266073
  4. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013
  5. Li D, Shi J, Dong X, Liang D, Jin J, He Y. Epidemiological characteristics and risk factors of lung adenocarcinoma: A retrospective observational study from North China. Front Oncol. 2022 Aug 5;12:892571. doi: 10.3389/fonc.2022.892571
  6. Cooper WA, Lam DC, O’Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013 Oct;5(Suppl 5):S479–S490. doi: 10.3978/j.issn.2072-1439.2013.08.03
  7. Lin L, Zhuang W, Wang W, Xu C, Chen R, Guan Y, Yi X, Shao Y, Tai Y, Chen Y, Wu M, Wei J, Chen G. Genetic mutations in lung enteric adenocarcinoma identified using next-generation sequencing. Int J Clin Exp Pathol. 2017 Sep 1;10(9):9583-9590. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966000/
  8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1): 7-30. doi: 10.3322/caac.21590
  9. Fujikawa R, Muraoka Y, Kashima J, Yoshida Y, Ito K, Watanabe H, Kusumoto M, Watanabe S, Yatabe Y. Clinicopathologic and genotypic features of lung adenocarcinoma characterized by the International Association for the Study of Lung Cancer grading system. J Thorac Oncol. 2022;17(6):741-753. doi: 10.1016/j.jtho.2022.02.005
  10. Zhan C, Yan L, Wang L, Sun Y, Wang X, Lin Z, Zhang Y, Shi Y, Jiang W, Wang Q. Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma. J Thorac Dis. 2015 Aug;7(8):1398-1405. doi: 10.3978/j.issn.2072-1439.2015.07.25
  11. Shah MA, Kennedy EB, Catenacci DVT, Deighton DC, Goodman KA, Malhotra NK, Willett C, Stiles B, Sharma P, Tang L, Wijnhoven BP, Hofstetter WL. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020 Aug 10;38(23):2677-2694. doi: 10.1200/JCO.20.00866
  12. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, Erickson N, Laviano A, Lisanti MP, Lobo DN, McMillan DC, Muscaritoli M, Ockenga J, Pirlich M, Strasser F, de van der Schueren M, Van Gossum A, Vaupel P, Weimann A. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017 Oct;36(5):1187-1196. doi: 10.1016/j.clnu.2017.06.017
  13. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015
  14. Kim B, Lee WW. Regulatory Role of Zinc in Immune Cell Signaling. Mol Cells. 2021;44(5):335-341. doi: 10.14348/molcells.2021.0061
  15. Ueland PM, McCann A, Midttun Ø, Ulvik A. Inflammation, vitamin B6 and related pathways. Mol Aspects Med. 2017;53:10-27. doi: 10.1016/j.mam.2016.08.001
  16. Nagao K, Yanagita T. Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res. 2010;61(3):208-212. doi: 10.1016/j.phrs.2009.11.007

Last update:

No citation recorded.

Last update:

No citation recorded.